Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending June 1, 2018. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital and voting rights data.
- Issued Share Capital (as of May 31, 2018): 5,374,127,654 Ordinary Shares of 25 pence each.
- Treasury Shares: 414,605,950 Ordinary Shares.
- Total Voting Rights: 4,959,521,704.
Material Changes
The filing text does not provide a clear value for material changes versus the prior comparable period. The document provides a static snapshot of share capital as of May 31, 2018, without comparative historical data.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The purpose of this specific filing is strictly to disclose the denominator for shareholder interest calculations under FCA rules.
Investor Verification Checklist
- Verify the total number of voting rights (4,959,521,704) to determine notification thresholds under FCA Disclosure Guidance and Transparency Rules.
- Confirm the number of shares held in Treasury (414,605,950) when calculating net outstanding shares.
- Review the Company's Form 20-F for comprehensive financial performance data, as this Form 6-K contains no financial results.